SCHEMBL30325765

SCHEMBL30325765

C=C(C)C(=O)Nc1ccc(-c2nn3ncnc(N)c3c2-c2ccc(C(=O)N3CCCC3)cc2)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ PIK3CD O00329 1/20 0.35
▸ TYRO3 Q06418 2/20 0.35
▸ ATR Q13535 4/20 0.34
▸ TNK2 Q07912 1/20 0.34
▸ JAK3 P52333 3/20 0.34
▸ PRKDC P78527 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ FGFR1 P11362 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ FGFR2 P21802 1/20 0.34
▸ FGFR4 P22455 1/20 0.34
▸ FGFR3 P22607 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ BCR P11274 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22676167 0.79 ATR (0.41) ALDH1A1TP53HPGDHTTPIK3CD
SCHEMBL22676347 0.79 FGFR1 (0.52) ALDH1A1TP53HPGDHTTATR
SCHEMBL22676439 0.78 ATR (0.41) ALDH1A1TP53HPGDHTTPIK3CD
SCHEMBL25129391 0.78 FGFR1 (0.52) ALDH1A1TP53HPGDHTTATR
SCHEMBL31213941 0.77 CYP3A4 (0.45) TNK2JAK3CYP3A4CYP2D6FGFR1
SCHEMBL31214014 0.77 CYP3A4 (0.61) TNK2JAK3CYP3A4CYP2D6FGFR1
SCHEMBL31213852 0.76 CYP3A4 (0.50) JAK3CYP3A4CYP2D6FGFR1CYP2C9
SCHEMBL30325642 0.75 CSNK2A2 (0.34) TNK2CYP3A4CYP2D6FGFR1CYP2C9
SCHEMBL22677463 0.74 ATR (0.40) ALDH1A1TP53HPGDHTTATR
SCHEMBL22676848 0.74 PLK4 (0.41) ALDH1A1TP53HPGDHTTPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US claimed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP claimed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO claimed
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US disclosed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP disclosed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR1, FGFR3, FGFR4 ALDH1A1 712/4885TP53 716/4885HPGD 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback